Novalgen Ltd.
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Subsidiary
- Established
- 2019-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.novalgen.com
Clinical Trials
1
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (100.0%)First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ Malignancies
Phase 1
Recruiting
- Conditions
- Small Lymphocytic LymphomaDiffuse Large B Cell LymphomaNon-small Cell Lung Cancer (NSCLC)Mantle Cell LymphomaFollicular LymphomaChronic Lymphocytic LeukaemiaMalignant Melanoma
- Interventions
- First Posted Date
- 2021-02-21
- Last Posted Date
- 2023-07-07
- Lead Sponsor
- NovalGen Ltd.
- Target Recruit Count
- 90
- Registration Number
- NCT04763083
- Locations
- 🇬🇧
University College London Hospital, London, United Kingdom
🇬🇧Royal Marsden Hospital, London, United Kingdom
🇬🇧The Christie NHS Foundation Trust, Manchester, United Kingdom
News
No news found